Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.53 |
| ▸ | KISS1R | Q969F8 | 13/20 | 0.53 |
| ▸ | EDNRA | P25101 | 1/20 | 0.49 |
| ▸ | GHSR | Q92847 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | CASP4 | P49662 | 1/20 | 0.49 |
| ▸ | CASP5 | P51878 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | CASP9 | P55211 | 1/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.49 |
| ▸ | CASP10 | Q92851 | 1/20 | 0.49 |
| ▸ | GLP1R | P43220 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29981546 | 1.00 | MAGI3 (0.53) | MAGI3KISS1REDNRAGHSRCASP1 | |
| SCHEMBL30261890 | 1.00 | MAGI3 (0.53) | MAGI3KISS1REDNRAGHSRCASP1 | |
| SCHEMBL30401759 | 0.86 | KISS1R (0.61) | KISS1RGLP1R | |
| SCHEMBL29982283 | 0.86 | KISS1R (0.62) | KISS1R | |
| SCHEMBL30401709 | 0.86 | KISS1R (0.62) | KISS1R | |
| SCHEMBL30202389 | 0.85 | KISS1R (0.53) | MAGI3KISS1REDNRAGHSRCASP1 | |
| SCHEMBL29516468 | 0.84 | EDNRA (0.61) | MAGI3KISS1REDNRA | |
| SCHEMBL30495707 | 0.84 | CCKBR (0.59) | KISS1RGLP1R | |
| SCHEMBL30906347 | 0.84 | GLP1R (0.56) | KISS1RGLP1R | |
| SCHEMBL29981946 | 0.84 | KISS1R (0.59) | KISS1RGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390508-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE-DRUG CONJUGATE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-11-28 | — | — | US | claimed |
| US-20240366775-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING ANTIBODY-PEPTIDE CONJUGATE | PEPTIDREAM INC. (JP) | 2024-11-07 | — | — | US | claimed |
| EP-4393959-A1 | HUMAN TRANSFERRIN RECEPTOR-BINDING ANTIBODY-PEPTIDE CONJUGATE | PeptiDream Inc. (JP) | 2024-07-03 | — | — | EP | claimed |
| EP-4389893-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE-DRUG CONJUGATE | Takeda Pharmaceutical Company Limited (JP) | 2024-06-26 | — | — | EP | claimed |
| US-20230203098-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE | JCR PHARMACEUTICALS CO., LTD. (JP) | 2023-06-29 | — | — | US | claimed |
| WO-2023027125-A1 | HUMAN TRANSFERRIN RECEPTOR-BINDING ANTIBODY-PEPTIDE CONJUGATE | ペプチドリーム株式会社 | 2023-03-02 | — | — | WO | claimed |
| WO-2023026994-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE-DRUG CONJUGATE | 武田薬品工業株式会社 | 2023-03-02 | — | — | WO | claimed |
| EP-4108676-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE | JCR Pharmaceuticals Co., Ltd. (JP) | 2022-12-28 | — | — | EP | claimed |
| CN-115151556-A | Human transferrin receptor binding peptides | JCR制药股份有限公司 | 2022-10-04 | — | — | CN | claimed |
| JP-2026032056-A | — | ＪＣＲファーマ株式会社 | 2026-02-25 | — | — | JP | disclosed |
| US-20240390508-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE-DRUG CONJUGATE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-11-28 | — | — | US | disclosed |
| US-20240390508-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE-DRUG CONJUGATE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-11-28 | — | — | US | disclosed |
| US-20240366775-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING ANTIBODY-PEPTIDE CONJUGATE | PEPTIDREAM INC. (JP) | 2024-11-07 | — | — | US | disclosed |
| US-20240366775-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING ANTIBODY-PEPTIDE CONJUGATE | PEPTIDREAM INC. (JP) | 2024-11-07 | — | — | US | disclosed |
| WO-2023027125-A1 | HUMAN TRANSFERRIN RECEPTOR-BINDING ANTIBODY-PEPTIDE CONJUGATE | ペプチドリーム株式会社 | 2023-03-02 | — | — | WO | disclosed |
| WO-2023027125-A1 | HUMAN TRANSFERRIN RECEPTOR-BINDING ANTIBODY-PEPTIDE CONJUGATE | ペプチドリーム株式会社 | 2023-03-02 | — | — | WO | disclosed |
| EP-4108676-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE | JCR Pharmaceuticals Co., Ltd. (JP) | 2022-12-28 | — | — | EP | disclosed |
| EP-4108676-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE | JCR Pharmaceuticals Co., Ltd. (JP) | 2022-12-28 | — | — | EP | disclosed |
| CN-115151556-A | Human transferrin receptor binding peptides | JCR制药股份有限公司 | 2022-10-04 | — | — | CN | disclosed |
| CN-115151556-A | Human transferrin receptor binding peptides | JCR制药股份有限公司 | 2022-10-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240390508-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE-DRUG CONJUGATE | MUSK, TFRC, SLC7A1 | MAGI3 3972/4885KISS1R 2887/4885EDNRA 106/4885 |
| US-20230203098-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING PEPTIDE | TFRC, SLC3A2, SLC7A1 | MAGI3 4579/4885KISS1R 1171/4885EDNRA 252/4885 |
| US-20240366775-A1 | HUMAN TRANSFERRIN RECEPTOR BINDING ANTIBODY-PEPTIDE CONJUGATE | TFRC, MET, SLC7A1 | MAGI3 2872/4885KISS1R 1979/4885EDNRA 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.